American Society of Clinical Oncology

SHERPA: White

People

  1. Dang
    Dang
  2. Hudis
    Hudis
  3. Norton
    Norton
  4. Modi
    Modi
  5. Traina
    Traina
  6. Lake
    Lake
  7. Fornier
    Fornier
  8. Iyengar
    Iyengar
  9. D'Andrea-Carlino
    D'Andrea-Carlino
  10. Chandarlapaty
    Chandarlapaty

Groups

  1. Breast Medicine Service (67)
  2. Department of Medicine (67)
  3. Solid Tumor Oncology Division (67)
  4. Survivorship Research (67)
  5. Population Sciences Research Program (33)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (29)
  7. Epidemiology and Biostatistics (24)
  8. Division of Subspecialty Medicine (23)
  9. Biostatistics Service (22)
  10. Cardiology (20)
Search Within
  1. "Chau Dang"
Formats
  1. Meeting Abstract (47)
  2. Journal Article (20)
Groups
  1. Breast Medicine Service (67)
  2. Department of Medicine (67)
  3. Solid Tumor Oncology Division (67)
  4. Survivorship Research (67)
  5. Population Sciences Research Program (33)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (29)

More Groups

People
  1. Chau Dang (67)
  2. Clifford Hudis (34)
  3. Larry Norton (25)
  4. Sujata Patil (16)
  5. Richard Steingart (15)
  6. Maura Dickler (14)

More People

Years
  1. 2024 (3)
  2. 2023 (2)
  3. 2022 (3)
  4. 2021 (4)
  5. 2020 (3)
  6. 2019 (4)

More Years

Publications
  1. Journal of Clinical Oncology (67)

Results (67)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I human epidermal growth factor receptor 2–positive breast cancer: 5-year results and correlative analyses from ATEMPT
    Journal Article

    Tarantino, P.; Tayob, N.; Villacampa, G.; Dang, C.; Yardley, D. A.; Isakoff, S. J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer
    Meeting Abstract

    Ferraro, E.; Moiso, E.; Safonov, A.; Cabel, L.; Loudon, L.; Dang, C. T.; Shen, S.; Jhaveri, K. L.; Robson, M. E.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Long-term follow-up of the anthracyclines in early breast cancer trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])
    Journal Article

    Geyer, C. E.; Blum, J. L.; Yothers, G.; Asmar, L.; Flynn, P. J.; Robert, N. J.; Hopkins, J. O.; O'Shaughnessy, J. A.; Rastogi, P.; Puhalla, S. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapy
    Meeting Abstract

    Yu, A. F.; Dang, C. T.; Jorgensen, J.; Moskowitz, C. S.; Wallins, J.; DeFusco, P. A.; Oligino, E.; Oeffinger, K. C.; Liu, J.; Steingart, R.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Meeting Abstract

    Chew, S.; Ferraro, E.; Chen, Y.; Barrio, A. V.; Kelly, D. W.; Modi, S.; Seidman, A. D.; Wen, H. Y.; Brogi, E.; Robson, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Quantification of methylation-specific cardiomyocyte cell-free DNA as an early marker of cardiotoxicity in patients with breast cancer receiving anthracyclines and trastuzumab
    Meeting Abstract

    Moore, Z. R.; Yu, A. F.; Liu, J.; Dang, C. T.; Oeffinger, K. C.; Steingart, R.; Schmitt, A.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Lacouture, M. E.; Pan, A.; Dranitsaris, G.; Harris, U.; Chandarlapaty, S.; Dang, C. T.; Gajria, D.; Gordon, A.; Iyengar, N. M.; Robson, M. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic
    Meeting Abstract

    Dang, C. T.; Tolaney, S. M.; Riaz, F.; Tan, A. R.; Tkaczuk, K. H. R.; Yu, A. F.; Liu, J.; Fung, A. M.; Yang, A.; Day, B. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial
    Meeting Abstract

    Sparano, J. A.; O'Neill, A. M.; Graham, N.; Northfelt, D. W.; Dang, C. T.; Wolff, A. C.; Sledge, G. W.; Miller, K.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Wang, R.; Singh, J. C.; Wong, S. T. L.; Lake, D.; Iyengar, N. M.; D'Andrea, G.; Brockway-Marchello, J. P.; Kaba, A.; Traina, T. A.; Robson, M. E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save